ASCO 2022 Conference Coverage
Playback speed
10 seconds
ASCO 2022 on the Addition of Carfilzomib as a Third Agent in Lenalidomide-Refractory MM: Switching From Doublet to Triplet
By
ASCO 2022 Conference Coverage
FEATURING
Claudio Cerchione
By
ASCO 2022 Conference Coverage
FEATURING
Claudio Cerchione
377 views
June 8, 2022
Comments 0
Login to view comments.
Click here to Login
Myeloma